

Extraordinary Report

March 31 , 2020

(TRANSLATION)

Note for readers of this English translation

On March 31, 2020, Chugai Pharmaceutical Co., LTD. (the “Company”) filed its Japanese-language Extraordinary Report (Rinji Houkokusho) (the “Report”) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 109th Annual General Meeting of Shareholders held on March 30, 2020 pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 109th Annual General Meeting of Shareholders (the “Meeting”) held on March 30, 2020, Chugai Pharmaceutical Co., Ltd (the “Company”) submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc.

2. Contents of the Extraordinary Report

(1) Date when the Meeting was held: March 30, 2020

(2) Matters for resolution

First Proposal Appropriation of Surplus

Year-end dividend

JPY 92 per share of common stock of the Company

Second Proposal Election of Four (4) Directors

Tatsuro Kosaka, Motoo Ueno, Osamu Okuda and Mariko Y Momoi were elected as directors of the Company.

Third Proposal Election of Two (2) Audit & Supervisory Board Members

Takaaki Nimura and Kenichi Masuda were elected as Audit & Supervisory Board Members of the Company.

Fourth Proposal Revision of Remuneration for Audit & Supervisory Board

Members

Remuneration for Audit & Supervisory Board Members was revised to be up to JPY120 million per year.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention" for each proposal; and Requirements for approving the proposals: Results of resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
First Proposal	5,145,475	5,404	0	99.89%	Approved
Second Proposal					
Tatsuro Kosaka	5,134,033	15,098	1,583	99.67%	Approved
Motoo Ueno	5,133,915	15,216	1,583	99.67%	Approved
Osamu Okuda	5,141,196	7,935	1,583	99.81%	Approved
Mariko Y Momoi	5,149,871	846	0	99.98%	Approved
Third Proposal					
Takaaki Nimura	5,150,432	286	0	99.99%	Approved
Kenichi Masuda	5,150,462	256	0	99.99%	Approved
Fourth Proposal	5,147,433	3,187	118	99.93%	Approved

Notes: Requirements for the approval of each proposal are as follows:

- 1) The resolution for the First and Fourth Proposal must be adopted by a majority of the votes of the shareholders present at the Meeting, who are entitled to exercise voting rights.
- 2) The resolution for the Second and Third Proposals must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.

(4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 30, 2020 was not added to the number of voting rights

Because in terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 30, 2020, as well as the votes exercised by a portion of shareholders present and

confirmed by the Company at the Meeting held on March 30, 2020; and the voting rights of the shareholders present at the Meeting held on March 30, 2020, untraceable with the final decision of "for", "against" or "abstention" as to each proposal were not tallied.